These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31771883)

  • 21. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
    Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
    Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 1'-Acetoxychavicol acetate inhibits growth of human oral carcinoma xenograft in mice and potentiates cisplatin effect via proinflammatory microenvironment alterations.
    In LL; Arshad NM; Ibrahim H; Azmi MN; Awang K; Nagoor NH
    BMC Complement Altern Med; 2012 Oct; 12():179. PubMed ID: 23043547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study.
    Nishio-Nagai M; Suzuki S; Yoshikawa K; Ueda R; Kazaoka Y
    Int J Oncol; 2017 Nov; 51(5):1471-1481. PubMed ID: 29048671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
    Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
    Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression.
    Wang X; Li H; Shi J
    Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell Carcinoma.
    Baird JR; Bell RB; Troesch V; Friedman D; Bambina S; Kramer G; Blair TC; Medler T; Wu Y; Sun Z; de Gruijl TD; van de Ven R; Leidner RS; Crittenden MR; Gough MJ
    Cancer Res; 2018 Nov; 78(21):6308-6319. PubMed ID: 30224374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
    Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose cisplatin converts the tumor microenvironment into a permissive state for HSVtk-induced antitumor immunity in HPV16-related tonsillar carcinoma.
    Goh AR; Shin SP; Jung NR; Ryu CH; Eom HS; Lee JH; Choi K; Lee SJ; Jung YS
    Cancer Lett; 2015 Jan; 356(2 Pt B):743-50. PubMed ID: 25449436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model.
    Gadkaree SK; Fu J; Sen R; Korrer MJ; Allen C; Kim YJ
    Head Neck; 2017 Jun; 39(6):1086-1094. PubMed ID: 28323387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
    Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y
    Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia-Targeting Multifunctional Nanoparticles for Sensitized Chemotherapy and Phototherapy in Head and Neck Squamous Cell Carcinoma.
    Song C; Tang C; Xu W; Ran J; Wei Z; Wang Y; Zou H; Cheng W; Cai Y; Han W
    Int J Nanomedicine; 2020; 15():347-361. PubMed ID: 32021184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8
    Hladíková K; Koucký V; Bouček J; Laco J; Grega M; Hodek M; Zábrodský M; Vošmik M; Rozkošová K; Vošmiková H; Čelakovský P; Chrobok V; Ryška A; Špíšek R; Fialová A
    J Immunother Cancer; 2019 Oct; 7(1):261. PubMed ID: 31623665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis.
    Chen X; Yan B; Lou H; Shen Z; Tong F; Zhai A; Wei L; Zhang F
    Mol Immunol; 2018 Apr; 96():28-36. PubMed ID: 29477933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
    Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
    Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cepharanthine Hydrochloride Improves Cisplatin Chemotherapy and Enhances Immunity by Regulating Intestinal Microbes in Mice.
    Zhou P; Li Z; Xu D; Wang Y; Bai Q; Feng Y; Su G; Chen P; Wang Y; Liu H; Wang X; Zhang R; Wang Y
    Front Cell Infect Microbiol; 2019; 9():225. PubMed ID: 31293986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apoptosis-promoting gene (bax) transfer potentiates sensitivity of squamous cell carcinoma to cisplatin in vitro and in vivo.
    Sugimoto C; Fujieda S; Seki M; Sunaga H; Fan GK; Tsuzuki H; Borner C; Saito H; Matsukawa S
    Int J Cancer; 1999 Sep; 82(6):860-7. PubMed ID: 10446454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RXRα-enriched cancer stem cell-like properties triggered by CDDP in head and neck squamous cell carcinoma (HNSCC).
    Jiang P; Xu C; Zhou M; Zhou H; Dong W; Wu X; Chen A; Feng Q
    Carcinogenesis; 2018 Feb; 39(2):252-262. PubMed ID: 29228308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.
    Wagenblast J; Hambek M; Baghi M; Gstöttner W; Strebhardt K; Ackermann H; Knecht R
    J Cancer Res Clin Oncol; 2008 Mar; 134(3):323-30. PubMed ID: 17701215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment.
    Ohkuri T; Ghosh A; Kosaka A; Zhu J; Ikeura M; David M; Watkins SC; Sarkar SN; Okada H
    Cancer Immunol Res; 2014 Dec; 2(12):1199-208. PubMed ID: 25300859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.